Key points are not available for this paper at this time.
Many genetic lesions have been identified in lung cancers. The findings shed light on molecular pathogenesis and have led to the definition of abnormalities that can be targeted by therapeutic agents that occasionally elicit dramatic responses.
Swanton et al. (Wed,) studied this question.